Patent application number | Description | Published |
20090249221 | METHODS AND SYSTEMS FOR ATTACHING AND DISPLAYING INTERACTIVE APPLICATIONS ON WEB PAGES - Methods and systems for facilitating interactive functions for an online community through a semi-transparent interactive application on a web page. The application may contain links to various interactive functions contextual to the web page displayed, and may provide functionality to the user because the various sessions do not open as pop-ups that block the viewing of the web page, or as a new tab or browser window, or as links directing the user to separate web pages; rather the sessions open as semi-transparent windows within the page that do not block the view of the underlying web page and are published seamlessly without having to reload the entire page again. | 10-01-2009 |
20100070889 | Methods for Bundling Disparate Sets of Web Resources to Unique String Identifiers - Methods for bundling disparate sets of web resources to unique string identifiers. The application may contain links to various interactive functions contextual to the web page displayed, and may provide functionality to the user because the various sessions do not open as pop-ups that block the viewing of the web page, or as a new tab or browser window, or as links directing the user to separate web pages; rather the sessions open as semi-transparent windows within the page that do not block the view of the underlying web page and are published seamlessly without having to reload the entire page again. The various interactive functions, such as discussions, shouts, polls and blogs, may be bundled as sets and mapped to certain unique identifiers, such as unique URLs, geocodes, UPC, ISBNs, etc. The bundle organization may be networked, or potentially form a containment hierarchy. By mapping to unique identifiers, the bundles of sets of functionality may create communities centered around a certain topic or book, or may create geographically centered communities. | 03-18-2010 |
Patent application number | Description | Published |
20090192807 | Identification of specialty drugs - Methods for determining whether a drug is a specialty drug, methods for creating tools to be used in making the determination, and the tools themselves are disclosed. The overall value of a drug depends on the drug's attribute values with respect to each of a set of drug attributes (concerning, e.g., the drug's route of administration, targeted disease, possible adverse reactions, risk of toxicity, cost, need for patient compliance with the treatment regime, and handling, preparation, and/or storage requirements. If the overall value or its partial overall values meet certain criteria, the drug is deemed to be a specialty drug. | 07-30-2009 |
20110307271 | IDENTIFICATION OF SPECIALTY DRUGS - Methods for determining whether a drug is a specialty drug, methods for creating tools to be used in making the determination, and the tools themselves are disclosed. The overall value of a drug depends on the drug's attribute values with respect to each of a set of drug attributes (concerning, e.g., the drug's route of administration, targeted disease, possible adverse reactions, risk of toxicity, cost, need for patient compliance with the treatment regime, and handling, preparation, and/or storage requirements. If the overall value or its partial overall values meet certain criteria, the drug is deemed to be a specialty drug. | 12-15-2011 |
20120084097 | IDENTIFICATION OF SPECIALTY DRUGS - Methods for determining whether a drug is a specialty drug, methods for creating tools to be used in making the determination, and the tools themselves are disclosed. The overall value of a drug depends on the drug's attribute values with respect to each of a set of drug attributes (concerning, e.g., the drug's route of administration, targeted disease, possible adverse reactions, risk of toxicity, cost, need for patient compliance with the treatment regime, and handling, preparation, and/or storage requirements. If the overall value or its partial overall values meet certain criteria, the drug is deemed to be a specialty drug. | 04-05-2012 |
Patent application number | Description | Published |
20090112296 | Scalar Laser Therapy Apparatus - There is disclosed a new low-level laser therapy apparatus and method of treating tissue. The invention includes a laser system that uses laser diodes and/or alternatively light emitting diodes (LED's), or both, and a digital interface that gives the operator the ability to generate sine waves or scalar waves as opposed to the simple on/off square waves. The invention also enables the operator to modulate not only the frequency, but also other wave characteristics such as the amplitude and phase. In one aspect, the invention involves modulating the phase relationship between multiple waves by taking one channel or wave which is pulsed through the laser system and then running a second channel or wave in relationship to the first channel, thereby creating a phased relationship, which has been discovered to provide a therapeutic and quantum healing effect on tissue. In one exemplary embodiment, the laser system of the invention may have a phase relationship of approximately 180 degrees which provides a beneficial therapeutic and quantum healing effect and, in particular, neutralizes or deletes cellular memory. | 04-30-2009 |
20110172747 | Scalar Laser Therapy Apparatus - There is disclosed a new low-level laser therapy apparatus and method of treating tissue. The invention includes a laser system that uses laser diodes and/or alternatively light emitting diodes (LED's), or both, and a digital interface that gives the operator the ability to generate sine waves or scalar waves as opposed to the simple on/off square waves. The invention also enables the operator to modulate not only the frequency, but also other wave characteristics such as the amplitude and phase. In one aspect, the invention involves modulating the phase relationship between multiple waves by taking one channel or wave which is pulsed through the laser system and then running a second channel or wave in relationship to the first channel, thereby creating a phased relationship, which has been discovered to provide a therapeutic and quantum healing effect on tissue. In one exemplary embodiment, the laser system of the invention may have a phase relationship of approximately 180 degrees which provides a beneficial therapeutic and quantum healing effect and, in particular, neutralizes or deletes cellular memory. | 07-14-2011 |
20130110207 | Scalar Laser Therapy Apparatus | 05-02-2013 |
Patent application number | Description | Published |
20090112296 | Scalar Laser Therapy Apparatus - There is disclosed a new low-level laser therapy apparatus and method of treating tissue. The invention includes a laser system that uses laser diodes and/or alternatively light emitting diodes (LED's), or both, and a digital interface that gives the operator the ability to generate sine waves or scalar waves as opposed to the simple on/off square waves. The invention also enables the operator to modulate not only the frequency, but also other wave characteristics such as the amplitude and phase. In one aspect, the invention involves modulating the phase relationship between multiple waves by taking one channel or wave which is pulsed through the laser system and then running a second channel or wave in relationship to the first channel, thereby creating a phased relationship, which has been discovered to provide a therapeutic and quantum healing effect on tissue. In one exemplary embodiment, the laser system of the invention may have a phase relationship of approximately 180 degrees which provides a beneficial therapeutic and quantum healing effect and, in particular, neutralizes or deletes cellular memory. | 04-30-2009 |
20110172747 | Scalar Laser Therapy Apparatus - There is disclosed a new low-level laser therapy apparatus and method of treating tissue. The invention includes a laser system that uses laser diodes and/or alternatively light emitting diodes (LED's), or both, and a digital interface that gives the operator the ability to generate sine waves or scalar waves as opposed to the simple on/off square waves. The invention also enables the operator to modulate not only the frequency, but also other wave characteristics such as the amplitude and phase. In one aspect, the invention involves modulating the phase relationship between multiple waves by taking one channel or wave which is pulsed through the laser system and then running a second channel or wave in relationship to the first channel, thereby creating a phased relationship, which has been discovered to provide a therapeutic and quantum healing effect on tissue. In one exemplary embodiment, the laser system of the invention may have a phase relationship of approximately 180 degrees which provides a beneficial therapeutic and quantum healing effect and, in particular, neutralizes or deletes cellular memory. | 07-14-2011 |
20130110207 | Scalar Laser Therapy Apparatus | 05-02-2013 |
20140142645 | Quantum Field System for Treatment of Human Tissue - There is disclosed a quantum field energy generating system that emits quantum energy to the body to provide a therapeutic and quantum effect to treat human tissue for health, rejuvenation and wellness. The quantum field generating system may include a housing, a printed circuit board contained within the housing, and a plurality of antennas positioned in the housing which may provide phased signals that provide a quantum field of energy for the treatment of human tissue. | 05-22-2014 |
Patent application number | Description | Published |
20080292618 | INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY - Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conjugate containing an agent effective in treating the disorder is administered to the patient. Also provided are methods of treating a patient having an autoimmune disorder involving administering to the patient a compound that inhibits a nucleoside transport pathway. | 11-27-2008 |
20100143358 | Use of Antibody Conjugates - Provided herein are methods for inducing growth arrest or apoptosis in cancer cells in a subject. Further provided are methods of inhibiting or treating metastasis of a cancer cell in a subject. The methods involve administering to the subject an antibody conjugate containing an antibody, variant thereof, or functional fragment thereof having binding specificity of the antibody as produced by the hybridoma having ATCC accession number PTA 2439 and a biologically active molecule. The antibody (e.g., mAb 3E10) variant or functional fragment thereof provides for the in vivo transduction of the conjugate to the nucleus of mammalian cells, where the conjugated biologically active molecule may exert its effect. In particular embodiments, the antibody conjugate comprises a single chain Fv fragment of an antibody having the binding specificity of mAb 3E10 produced by ATCC PTA 2439, conjugated to p53. | 06-10-2010 |
20120070875 | Amino Acid Sequences which Enhance Peptide Conjugate Solubility - The present invention provides peptide conjugates having improved solubility as well as increased secretion during cell based production, as well as methods of utilizing such peptides. The peptide conjugates include a short peptide domain defined by the amino acid sequence AGIH (SEQ ID NO: 8) and may include a biologically active molecule useful in intracellular and intranuclear transport of the biologically active molecule to treat various disorders and diseases. | 03-22-2012 |
20140050723 | Cell-Penetrating Anti-DNA Antibodies and Uses Thereof Inhibit DNA Repair - Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies. | 02-20-2014 |
Patent application number | Description | Published |
20120258461 | METHODS FOR DETERMINING AND INHIBITING RHEUMATOID ARTHRITIS ASSOCIATED WITH THE BRAF ONCOGENE IN A SUBJECT - The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the BRAF oncogene; and culturing the sample in the presence of the agent and determining whether BRAF oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene. | 10-11-2012 |
20130259862 | ANTIBODY-MEDIATED TRANSDUCTION OF HEAT SHOCK PROTEINS INTO LIVING CELLS - The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus. | 10-03-2013 |
20130266570 | Targeting Intracellular Target-binding Determinants with Intracellular Antibodies - The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target. | 10-10-2013 |
20140200260 | METHODS FOR DETERMINING AND INHIBITING RHEUMATOID ARTHRITIS ASSOCIATED WITH THE BRAF ONCOGENE IN A SUBJECT - The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the BRAF oncogene; and culturing the sample in the presence of the agent and determining whether BRAF oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene. | 07-17-2014 |
20140234309 | Antibody-mediated transduction of heat shock proteins into living cells - The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus. | 08-21-2014 |